ABBVCL Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
AbbVie Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$180,620.00 |
| 52 Week High | US$180,620.00 |
| 52 Week Low | US$179,870.00 |
| Beta | 0.62 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABBVCL | CL Biotechs | CL Market | |
|---|---|---|---|
| 7D | n/a | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how ABBVCL performed against the CL Biotechs industry.
Return vs Market: Insufficient data to determine how ABBVCL performed against the CL Market.
Price Volatility
| ABBVCL volatility | |
|---|---|
| ABBVCL Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in CL Market | 0% |
| 10% least volatile stocks in CL Market | 0% |
Stable Share Price: ABBVCL has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ABBVCL's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 50,000 | Robert Michael | www.abbvie.com |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
AbbVie Inc. Fundamentals Summary
| ABBVCL fundamental statistics | |
|---|---|
| Market cap | CL$320.05t |
| Earnings (TTM) | CL$4.89t |
| Revenue (TTM) | CL$50.81t |
65.4x
P/E Ratio6.3x
P/S RatioIs ABBVCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABBVCL income statement (TTM) | |
|---|---|
| Revenue | US$55.00b |
| Cost of Revenue | US$16.69b |
| Gross Profit | US$38.31b |
| Other Expenses | US$33.02b |
| Earnings | US$5.30b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.00 |
| Gross Margin | 69.66% |
| Net Profit Margin | 9.63% |
| Debt/Equity Ratio | 1,040.0% |
How did ABBVCL perform over the long term?
See historical performance and comparison